Japan’s Kyowa Inks Deal with Taiwan’s CDMO Firm to Manufacture Generic Drugs

by Tyler Chen
Share To

Japanese drugmaker Kyowa Pharma and Taiwan’s CDMO firm Bora Pharmaceuticals announced a manufacturing pact on August 5th. As per the terms, Bora will help produce Kyowa’s generic products at its Zhunan site in Taiwan, but the details remain undisclosed.


Kyowa’s Focus on CNS Drugs

Kyowa has been in the industry for over 65 years. The firm is best known for developing generic drugs for treating patients with central nervous system (CNS) diseases, which take up over 59% of the company’s portfolio. Its pipeline includes Neuropsychiatric drugs, antiparkinsonian drugs, ​​anxiolytics, and antiepileptic. Other than CNS drugs, Kyowa also invests in developing cardiovascular medicines.


Support for BE Studies and Commercial Production

Bora said it will deliver batches for bioequivalence (BE) studies and handle the submission to Japan’s PMDA for approval. Bora will be the commercial manufacturing site for the generic product if the drugs get the nod.

The Zhunan plant has gained approval from the USFDA (2009), TFDA (2010), and MHRA (2015). It is a 36,000 plus square meter CMO facility with cGMP compliant manufacturing and packaging services. Other than that, Bora has two other sites, one in Tainan, Taiwan, and the other in Ontario, Canada.

Upon the deal, Kyowa will become Bora’s first Japanese client.

© All rights reserved. Collaborate with us:
Related Post
Taiwan’s Biotech Brilliance Shines at BIO 2023: Unveiling Cutting-Edge Discoveries and Strategic Partnerships
Bora and Celltrion Join Forces To Distribute Oral Drugs Across APAC
Forge Biologics Raises $90 Million To Expand Gene Therapy CDMO
Ginkgo Bioworks and Pfizer Forge $331 Million Collaboration for RNA-Based Drug Discovery
Johnson & Johnson Partners with Singapore to Boost Life Sciences Innovation
Vietnam and South Korea Strengthen Cooperation in Multiple Sectors
PeptiDream and Genentech Collaborate on Novel Peptide-Radioisotope Drug Conjugates
AcuraStem and Takeda Collaborate on Innovative ALS Treatment
Seven AI/ML for Life Sciences Companies Identified as Innovators in New Clarivate Companies to Watch Report
GeneOnline’s Weekly News Highlights: Sept 17-Sept 22
BioFuture 2023
New York city,USA
Scroll to Top